Please use this identifier to cite or link to this item:
|Title:||Restrictive versus liberal fluid therapy in major abdominal surgery (RELIEF): rationale and design for a multicentre randomised trial.|
|Authors:||Myles, Paul;Bellomo, Rinaldo;Corcoran, Tomas;Forbes, Andrew;Wallace, Sophie;Peyton, Philip J;Christophi, Christopher;Story, David;Leslie, Kate;Serpell, Jonathan;McGuinness, Shay;Parke, Rachel|
|Affiliation:||Alfred Hospital, Melbourne, Victoria, Australia|
Monash University, Melbourne, Victoria, Australia
University of Western Australia, Melbourne, Victoria, Australia..
Monash University, Melbourne, Victoria, Australia..
Austin Hospital, Heidelberg, Victoria, Australia
The University of Melbourne, Melbourne, Victoria, Australia
Royal Melbourne Hospital, Melbourne, Victoria, Australia..
Auckland City Hospital, Auckland, New Zealand
|Citation:||BMJ open 2017; 7(3): e015358|
|Abstract:||The optimal intravenous fluid regimen for patients undergoing major abdominal surgery is unclear. However, results from many small studies suggest a restrictive regimen may lead to better outcomes. A large, definitive clinical trial evaluating perioperative fluid replacement in major abdominal surgery, therefore, is required. We designed a pragmatic, multicentre, randomised, controlled trial (the RELIEF trial). A total of 3000 patients were enrolled in this study and randomly allocated to a restrictive or liberal fluid regimen in a 1:1 ratio, stratified by centre and planned critical care admission. The expected fluid volumes in the first 24 hour from the start of surgery in restrictive and liberal groups were ≤3.0 L and ≥5.4 L, respectively. Patient enrolment is complete, and follow-up for the primary end point is ongoing. The primary outcome is disability-free survival at 1 year after surgery, with disability defined as a persistent (at least 6 months) reduction in functional status using the 12-item version of the World Health Organisation Disability Assessment Schedule. The RELIEF trial has been approved by the responsible ethics committees of all participating sites. Participant recruitment began in March 2013 and was completed in August 2016, and 1-year follow-up will conclude in August 2017. Publication of the results of the RELIEF trial is anticipated in early 2018. ClinicalTrials.gov identifier NCT01424150.|
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
INTENSIVE & CRITICAL CARE
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.